Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma

Related Experiment Videos

K H Lin1, X G Zhu, H C Hsu

  • 1Department of Biochemistry, Chang-Gung College of Medicine and Technology, Taoyuan, Taiwan. cguaplo.cgu.tw.edu.

Endocrinology
|December 6, 1997
PubMed

Insights

Mutations in thyroid hormone receptors (TR alpha1) found in liver cancer patients impair hormone binding and alter DNA binding. These novel TR alpha1 mutants demonstrate dominant negative activity, offering insights into mutant receptor function.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Thyroid hormone receptors (TRs) are crucial nuclear receptors regulating gene expression.
  • Mutations in TR genes can lead to altered receptor function and disease.
  • TR alpha1 specifically plays a role in various physiological processes.

Purpose of the Study:

  • To isolate and characterize novel mutant thyroid hormone alpha1 receptors (TR alpha1) from hepatocellular carcinoma patients.
  • To investigate the impact of specific mutations on TR alpha1 hormone-binding, DNA-binding, and dominant negative activities.
  • To elucidate the molecular mechanisms underlying the dominant negative action of mutant TR alpha1.

Main Methods:

  • Complementary DNA (cDNA) isolation from patient tumor samples.
  • DNA sequencing to identify mutations (Val390Ala in mutant H; Pro398Ser/Glu350Lys in mutant L).
  • In vitro characterization of hormone-binding, DNA-binding to various thyroid hormone response elements (TREs), and dominant negative activity assays.

Main Results:

  • Mutants H and L exhibited no T3 hormone-binding activity.
  • DNA-binding of mutant L was significantly reduced (~90%) to all tested TREs as homodimers.
  • Mutant H showed complex DNA-binding, with reduced binding to Lys (~80%) but enhanced binding to Pal TREs as homodimers; heterodimerization with RXR was unaffected.
  • Both mutants lost trans-activation capacity and displayed dominant negative activity, with TRE-dependent potency for mutant H and TRE-independent for mutant L.

Conclusions:

  • TR alpha gene mutations can occur in patients with hepatocellular carcinoma.
  • The novel TR alpha1 mutants (H and L) exhibit distinct alterations in DNA-binding and dominant negative activities.
  • These mutants serve as valuable tools for understanding the molecular basis of dominant negative effects of mutant TRs.

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...